| WB | 1/200-1/1000 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/1000-1/2000 | Human,Mouse,Rat |
| Aliases | M1; HM1; M1R |
| WB Predicted band size | 51 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human, Mouse, Rat |
| Immunogen | Fusion protein of human CHRM1 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是关于CHRM1抗体的3篇参考文献概述，供参考：
1. **文献名称**：*"Selective Antibody-Based Targeting of M1 Muscarinic Receptors in Alzheimer's Disease Models"*
**作者**：Smith A et al.
**摘要**：研究报道了一种高特异性CHRM1抗体的开发，验证其在阿尔茨海默病小鼠模型中检测受体表达下降的能力，并探讨其作为治疗靶点的潜力。
2. **文献名称**：*"CHRM1 Antibody Validation for Immunohistochemistry in Postmortem Human Brain Tissue"*
**作者**：Lee J et al.
**摘要**：该文献系统验证了CHRM1抗体在人类脑组织中的特异性，证明其在精神分裂症患者前额叶皮层中的表达异常，支持CHRM1与认知功能障碍的关联。
3. **文献名称**：*"Pharmacological Characterization of a Novel CHRM1 Monoclonal Antibody in Neuropathic Pain Models"*
**作者**：Chen R et al.
**摘要**：研究利用新型CHRM1抗体揭示受体在神经病理性疼痛中的调控作用，证实抗体可阻断M1受体信号通路并缓解疼痛行为。
4. **文献名称**：*"Cross-Reactivity Assessment of Commercial CHRM1 Antibodies Using Knockout Validation Strategies"*
**作者**：Garcia M et al.
**摘要**：通过基因敲除模型评估市售CHRM1抗体的特异性，发现部分抗体存在非特异性结合，强调抗体选择对研究可靠性的重要性。
(注：以上文献为模拟示例，实际引用需核实真实来源。)
The cholinergic receptor muscarinic 1 (CHRM1) antibody is a tool used to detect and study the M1 subtype of muscarinic acetylcholine receptors, which are G protein-coupled receptors (GPCRs) critical for mediating acetylcholine signaling in the central and peripheral nervous systems. CHRM1 is predominantly expressed in the brain (e.g., cortex, hippocampus) and plays a key role in cognitive functions, including memory, learning, and synaptic plasticity. It activates Gq/11 proteins, triggering downstream pathways like phospholipase C (PLC) activation, which regulates neuronal excitability and neurotransmitter release. Dysregulation of CHRM1 is implicated in neurological disorders such as Alzheimer’s disease, schizophrenia, and Parkinson’s disease.
CHRM1 antibodies are widely used in research to localize, quantify, and analyze receptor expression and function. They enable techniques like immunohistochemistry (IHC), Western blotting, and flow cytometry, aiding in the investigation of receptor distribution, signaling mechanisms, and therapeutic targeting. Monoclonal antibodies offer high specificity, while polyclonal versions may detect multiple epitopes. Validation parameters such as species reactivity, sensitivity, and cross-reactivity with other muscarinic subtypes (e.g., M2-M5) are critical to ensure experimental accuracy. Recent advancements in antibody engineering have improved their utility in studying CHRM1’s role in disease models and drug development, particularly for therapies aiming to modulate cholinergic signaling in neurodegenerative and psychiatric conditions.
×
